Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDE8B | O95263 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420888 | 1.00 | ATM (0.42) | ATMHSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL7923096 | 1.00 | ATM (0.42) | ATMHSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL1061613 | 0.91 | HSD17B10 (0.46) | ATMHSD17B10PDE8BSMN1; SMN2ALDH1A1 | |
| SCHEMBL1427736 | 0.91 | HSD17B10 (0.46) | ATMHSD17B10PDE8BSMN1; SMN2ALDH1A1 | |
| SCHEMBL86228 | 0.91 | HSD17B10 (0.46) | ATMHSD17B10PDE8BSMN1; SMN2ALDH1A1 | |
| SCHEMBL23015233 | 0.89 | PDE8B (0.47) | ATMHSD17B10HPGDPDE8BSMN1; SMN2 | |
| SCHEMBL31037649 | 0.89 | PDE8B (0.47) | ATMHSD17B10HPGDPDE8BSMN1; SMN2 | |
| SCHEMBL1009587 | 0.89 | PDE8B (0.47) | ATMHSD17B10HPGDPDE8BSMN1; SMN2 | |
| SCHEMBL1398690 | 0.87 | HTT (0.43) | ATMHSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL1630474 | 0.87 | HTT (0.43) | ATMHSD17B10CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-109942565-B | Indoleamine-2, 3-dioxygenase inhibitor and preparation method and application thereof | 海创药业股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008060767-A2 | MACROCYCLIC BENZOFUSED PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | ATM 570/4885HSD17B10 1213/4885CHRM2 4850/4885 |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | ATM 291/4885HSD17B10 3677/4885CHRM2 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.